An injection of GCSF into the AML (AML+GCSF)-treated group did not affect the percentage of tubules with more than 15 ACROSIN-positive cells compared to CT 2 weeks post-injection (Figure 7B). The gene discussed is CSF3; the disease is acute myeloid leukemia.